Status:
COMPLETED
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Lead Sponsor:
Pfizer
Conditions:
Neoplasm, Malignant
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.
Eligibility Criteria
Inclusion
- Patients with a diagnosis of a solid malignancy that is refractory to standard therapy or for which no standard therapy exists.
- Patients has a good performance status (ECOG 0 or 1)
Exclusion
- Prior treatment with either pemetrexed or SU011248.
- Coughing up blood within 4 weeks before starting study treatment (small amounts okey).
- Hypertension that cannot be controlled by medications.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00732992
Start Date
August 1 2008
End Date
November 1 2009
Last Update
March 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Osakasayama-shi, Osaka, Japan